Role of activin in bacterial infections: A potential target for immunointervention?

Immunotherapy

Volumn 2, Issue 5, 2010, Pages 673-684

  Ebert, Sandra ^a   Nau, Roland ^a,b   Michel, Uwe ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Sleep Laboratory   (Germany)

Author keywords

activin; follistatin; immunotherapy; infection; inflammation; innate immunity; meningitis; sepsis

Indexed keywords

ACTIVIN A; FOLLISTATIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

BACTERIAL INFECTION; HUMAN; INFLAMMATION; MENINGITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SEPSIS; SIGNAL TRANSDUCTION;

ACTIVINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIAL INFECTIONS; FOLLISTATIN; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS;

EID: 77957581406     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.64     Document Type: Review

References (85)

1. Phillips DJ: The activin/inhibin family. In: The Cytokine Handbook. 4th Edition, Volume 2. Thomson A, Lotze MT (Eds). Academic Press, London, UK, 1153-1177 (2003).
2. McDowall M, Edwards NM, Jahoda CAB, Hynd PI: The role of activins and follistatins in the skin and hair follicle development and function. Cytokine Growth Factor Rev. 19, 415-426 (2008).
3. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H: Activin-binding protein from rat ovary is follistatin. Science 246, 836-838 (1990).
4. De Winter JP, ten Dijke P, De Vries CJM et al.: Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors. Mol. Cell. Endocrinol. 116, 105-114 (1996).
5. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H: A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparin sulfate. J. Biol. Chem. 272, 13835-13842 (2007).
6. Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB: The structure of FSTL3 activin A complex. Differential binding of N-terminal domains infuences follistatin-type antagonist specificity. J. Biol. Chem. 283, 32831-32838 (2008).
7. Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A: Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenic proteins. Endocrinology 147, 3586-3597 (2006).
8. Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann H, Krasney PA: Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology 149, 4589-4595 (2008).
9. Phillips DJ, De Kretser DM, Hedger MP: Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 20, 153-164 (2009). □ Excellent current review on the emerging role of activin in inflammation.
10. Hübner G, Brauchle M, Gregor M, Werner S: Activin A: a novel player and inflammatory marker of in inflammatory bowed disease? Lab. Invest. 77, 311-318 (1997).
11. Karagiannidis C, Hense G, Martin C et al.: Activin A is an acute allergen-responsive cytokine and provides a link to TGF-β-mediated airway remodeling in asthma. J. Allergy Clin. Immunol. 117, 111-118 (2006).
12. Yu EW, Dolter KE, Shao L-E, Yu J: Suppression of IL-6 biological activities by activin A and implications for inflammatory arthropathies. Clin. Exp. Immunol. 112, 126-132 (1998).
13. Ota F, Maeshima A, Yamashita S et al.: Actvin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheumatism 48, 2442-2449 (2003).
14. McLean CA, Cleland H, Monerieff NJ, Barton RJ, De Kretser DM, Phillips DJ: Temporal expression of activin in acute burn wounds from inflammatory cells to fibroblasts. Burns 34, 50-55 (2008).
15. Smith C, Yndestad A, Halvorsen B et al.: Potential anti-inflammatory role of activin A in acute coronary syndromes. J. Am. Coll. Cardiol. 44, 369-375 (2004).
16. Phillips DJ, Jones KL, Scheerlinck J-PY, Hedger MP, De Kretser DM: Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol. Cell. Endocrinol. 180, 155-162 (2001).
17. Phillips DJ, Nguyen P, Adamides AA et al.: Activin A release into cerebrospinal fluid in a subset of patients with severe traumatic brain injury. J. Neurotrauma 23, 1283-1294 (2006).
18. Michel U, Shintani Y, Nau R: Serum follistatin concentrations are increased in patients with septicaemia. Clin. Endocrinol. 48, 413-417 (1998).
19. Michel U, Ebert S, Phillips D, Nau R: Serum concentrations of activin and follistatin are elevated and run in parallel in patients with septicemia. Eur. J. Endocrinol. 148, 559-564 (2003).
20. Schubert D, Kimura H, La Corbiere M, Vaughan J, Karr D, Fischer WH: Activin is a nerve cell survival molecule. Nature 344, 868-870 (1990).
21. Krieglstein K, Suter-Crazzolara C, Fischer WH, Unsicker K: TGF-β superfamiliy members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. EMBO J. 14, 736-742 (1996).
22. Iwahori Y, Saito H, Torii K, Nishiyama N: Activin exerts a neurotrophic effect on cultured hippocampal neurons. Brain Res. 760, 52-58 (1997).
23. Hughes PE, Alexi T, Williams CE, Clark RG, Gluckman PD: Administration of recombinant human activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolonic acids lesion model of Huntington's disease. Neuroscience 92, 197-209 (1999).
24. Ebert S, Phillips DJ, Jenzewski P, Nau R, O'Connor AE, Michel U: Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis. J. Neurol. Sci. 250, 50-57 (2006).
25. Wilms H, Schwark T, Brandenburg L-O et al.: Regulation of activin A synthesis in microglial cells: pathophysiological implications or bacterial meningitis. J. Neurosci. Res. 88, 16-23 (2010).
26. Michel U, Gerber J, O'Connor AE et al.: Increased activin levels in cerebrospinal fluid of rabbits with bacterial meningitis are associated with activation of microglia. J. Neurochem. 86, 238-245 (2003).
27. Michel U, Ebert S, Schneider O et al.: Follistatin (FS) in human cerebrospinal fluid and regulation of FS expression in a mouse model of meningitis. Eur. J. Endocrinol. 143, 809-816 (2000).
28. Jones KL, Braumann JN, Groome NP, De Kretser DM, Phillips DJ: Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 141, 1905-1908 (2000).
29. Jones KL, De Kretser DM, Clarke IJ, Scheerlinck J-PY, Phillips DJ: Characterisation of the rapid release of activin A following acute lipopolysaccharide challenge in the ewe. J. Endocrinol. 182, 69-80 (2004). □ Key article describing the potential of follistatin (FS) to reduce mortality in a mouse model of acute systemic inflammation.
30. McClure L, O'Connor AE, Hayward S, Jenkin G, Walker DW, Phillips DJ: Effects of age and pregnancy on the circulatory activin response of sheep to acute inflammatory challenge by lipopolysaccharide. J. Endocrinol. 185, 139-149 (2005).
31. Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, De Kretser DM, Phillips DJ: Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl Acad. Sci. USA 104, 16239-16244 (2007).
32. Klein R, Clarke IJ, Hedger MP, Robertson DM: Plasma follistatin concentrations increase following lipopolysaccharide administration in sheep. Clin. Exp. Pharmacol. Physiol. 23, 754-755 (1996).
33. Phillips DJ, Hedger MP, McFarlane JR et al.: Follistatin concentrations in male sheep increase following sham castration/castration or injection of interleukin-1β. J. Endocrinol. 151, 119-124 (1996).
34. Phillips DJ, De Kretser DM, Pfeffer A, Ng Chic W, Moore LG: Follistatin has a biphasic response but follicle-stimulating hormone is unchanged during an inflammatory episode in growing lambs. J. Endocrinol. 156, 77-82 (1998).
35. Erämaa M, Hurme M, Steaman U-H, Ritvos O: Activin A/erythroid differentiation factor is induced during human monocytic activation. J. Exp. Med. 176, 1449.1452 (1992).
36. Shao L-E, Frigon NL Jr, Schy DW et al.: Regulation of production of activin A in human marrow stromal cells and monocytes. Exp. Hematol. 20, 1235-1242 (1992).
37. Yu J, Shao L-E, Frigon NL Jr, Lofgren J, Schwall R: Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid. Immunology 88, 368-374 (1996).
38. Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin L-L: Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J. Immunol. 180, 3520-3534 (2008).
39. Ogawa K, Funaba M, Mathews LS, Mizutani T: Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages. J. Immunol. 165, 2997-3003 (2000).
40. Wang S-Y, Tai G-X, Zhang P-Y, Mu D-P, Zhang X-J, Liu Z-H: Inhibitory effect of activin A on activation of lipopolysaccharidestimulated mouse macrophage RAW264.7 cells. Cytokine 42, 85-91 (2008).
41. Ebert S, Zeretzke M, Nau R, Michel U: Microglial cells and peritoneal macrophages release activin A upon stimulation with Toll-like receptor agonists. Neurosci. Lett. 413, 241-244 (2007).
42. Robson NC, Phillips DJ, McAlpine T et al.: Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. Blood 111, 2733-2743 (2008).
43. Shao L-E, Frigon Jr NL, Yu A, Palyash J, Yu J: Contrasting effects of inflammatory cytokines and glucocorticoids on the production of activin A in human marrow stromal cells and their implications. Cytokine 10, 227-235 (1998).
44. Takahashi, S, Uchimaru K, Harigaya K, Asano S, Yamashita T: Tumor necrosis factor and interleukin-I induce activin A gene expression in a human bone marrow stromal cell line. Biochem. Biophys. Res. Commun. 188, 310-317 (1992).
45. Yamashita T, Takahashi S, Ogata E: Expression of activin A/erythroid differentiation factor in murine bone marrow stromal cells. Blood 79, 304-307 (1992).
46. Abe M, Shintani Y, Eto Y et al.: Interleukin-1β enhances and intereron-γ suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts. Clin. Exp. Immunol. 126, 64-68 (2001).
47. Ogawa K, Funaba M, Chen Y, Tsujimoto M: Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J. Immunol. 177, 6787-6794 (2006).
48. Cho SH, Yoa Z, Wang S-W et al.: Regulation of activin A expression in mast cells and asthma: its effect on the proliferation of human airway smooth muscle cells. J. Immunol. 179, 4045-4052 (2003).
49. Ogawa K, Funaba M, Tsujimoto M: A dual role of activin A in regulating immunoglobulin production of B cells. J. Leukoc. Biol. 83, 1451-1458 (2008).
50. Michel U, Schneider P, Kirchhof C et al.: Production of follistatin in porcine endothelial cells: differential regulation by bacterial compounds and the synthetic glucocorticoid RU 28362. Endocrinology 137, 4925-4934 (1996).
51. Wilson KM, Smith AI, Phillips DJ: Stimulatory effects of lipopolysaccharisde on endothelial cell activin and follistatin. Mol. Cell. Endocrinol. 253, 30-35 (2006).
52. Kariyawasam HH, Pegorier S, Barkans J et al.: Activin and transforming growth factor-β signaling pathways are activated after allergen challenge in mild asthma. J. Allergy Clin. Immunol. 124, 454-462 (2009).
53. Hübner G, Werner S: Serum growth factors and proinflammatory cytokines are potent inducers of activin expressioin in cultured fibroblasts and keratinocytes. Exp. Cell. Res. 228, 106-113 (1996).
54. Okuma Y, O'Connor AE, Muir JA, Stanton PG, De Kretser DM, Hedger MP: Regulation of activin A and inhibin B secretion by inflammatory mediators in adult rat Sertoli cell cultures. J. Endocrinol. 187, 125-134 (2005).
55. Winnall WR, Muir JA, Hedger MP: Differential responses of epithelial Sertoli cells of the rat testis to Toll-Like receptor 2 and 4 ligands: implications for studies of testicular inflammation using bacterial lipopolysaccharides. Innate Immun. DOI: 10.1177/1753425909354764 (2009) (Epub ahead of print).
56. Tsuchida K: Activins, myostatin and related TGF-β family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr. Drug Targets Immun. Endocr. Metabol. Disord. 4, 157-166 (2004).
57. Tsuchida K, Nakatani M, Hitachi K et al.: Activin signaling as an emerging target for therapeutic interventions. Cell. Commun. Signal. 7, 15 (2009). □ Excellent current review on the various strategies that have been designed to manipulate activin signaling and their therapeutic potential.
58. Semitekolou M, Alissafi T, Aggelakopoulou M et al.: Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease. J. Exp. Med. 206, 1769-1785 (2009).
59. Engelse MA, Lardenoye JH, Neele JM et al.: Adenoviral activin a expression prevents intimal hyperplasia in murine blood vessels by maintaining the contractile smooth muscle cell phenotype. Circ. Res. 31, 1128-1234 (2002).
60. Kloppenburg GTL, Grauls GE, Bruggeman CA, Stassen FR: Adenoviral activin A expression prevents vein graft intimal hyperplasia in a rat model. Interact. Cardiovasc. Thorac. Surg. 8, 31-34 (2009).
61. Tsuchida K, Nakatani M, Matsuzaki T et al.: Novel factors in regulation of activin signaling. Mol. Cell. Endocrinol. 255, 1-8 (2004).
62. Fajardo RJ, Manoharan RK, Pearsall RS et al.: Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 46, 64-71 (2010).
63. Ruckle J, Jacobs M, Kramer W et al.: Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J. Bone Miner. Res. 24, 744-752 (2009). □ Describes the successful therapeutic use of blocking activin actions by Act RIIA-IgG1 in humans.
64. Morrison BM, Lachey JL, Warsing LC et al.: A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 217, 258-268 (2009).
65. Li Q, Kumar R, Underwood K et al.: Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol. Hum. Reprod. 13, 675-683 (2007).
66. Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR: Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 39, 283-296 (2009).
67. Aoki F, Kojima I: Therapeutic potential of follistatin to promote tissue regeneration and prevent tissue fibrosis. Endocrin. J. 54, 849-854 (2007).
68. Dohi T, Ejima C, Kato R et al.: Therapeutic potential of follistatin for colonic infammation in mice. Gastroenterology 128, 411-423 (2005).
69. Hardy CL, O'Connor AE, Yao J et al.: Follistatin is a candidate endogenous negative regulator of activin A in experimental allergic asthma. Clin. Exp. Allergy 36, 941-950 (2006).
70. Ge J, Wang Y, Feng Y et al.: Direct effects of activin A on the activation of mouse macrophage RAW264.7 cells. Cell. Mol. Immunol. 6, 129-133 (2009).
71. Yamashita N, Nakajima T, Takahashi H, Kaneoka H, Mizushima Y, Sakane T: Effects of activin A on IgE synthesis and cytokine production by human peripheral mononuclear cells. Clin. Exp. Immunol. 94, 214-219 (1993).
72. Zhang X, Li Y, Tai G et al.: Effects of activin A on the activities of mouse peritoneal macrophages. Cell. Mol. Immunol. 2, 63-67 (2005).
73. Nüsing RM, Mohr S, Ullrich V: Activin A and retinoic acid synergize in cyclooxygenase-I and thromboxane synthase induction during differentiation of J774.1 macrophages. Eur. J. Biochem. 227, 130-136 (1995).
74. Sugama S, Takenouchi T, Kitani H, Fujita M, Hashimoto M: Activin as an antiinfammatory cytokine produced by microglia. J. Neuroimmunol. 192, 31-39 (2007).
75. Nüsing RM, Barsig J: Induction of prostanoid, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A. Br. J. Pharmacol. 127, 919-926 (1999).
76. Salogni L, Musso T, Boisio D et al.: Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood 113, 5848-5856 (2009).
77. Funaba M, Ikeda T, Ogawa K, Murakami M, Abe M: Role of activin A in murine mast cells: modulation of cell growth, differentiation, and migration. J. Leuk. Biol. 73, 793-801 (2003).
78. + induced regulatory T cells. J. Immunol. 182, 4622-4640 (2009).
79. Ohguchi M, Yamato K, Ishihara Y et al.: Activin A regulates the production of mature interleukin-1β and interleukin-I receptor antagonist in human monocytic cells. Cytokine Res. 18, 491-498 (1998).
80. Zhou J, Tai G, Liu H et al.: Activin A down-regulates the phagocytosis of lipopolysaccharide-activated mouse peritoneal macrophages in vitro and in vivo. Cell. Immunol. 255, 69-75 (2009).
81. Scutera S, Riboldi E, Daniele R et al.: Production and function of activin A in human dendritic cells. Eur. Cytokine Netw. 19, 60-68 (2008).
82. Segerer SE, Müller N, van den Brandt J et al.: The glycoprotein-hormones activin A and inhibin A interfere with dendritic cell maturation. Reprod. Biol. Endocrinol. 6, 17-27 (2008).
83. Robson NC, Wei H, McAlpine T, Kirkpatrick N, Cebon J, Maraskovsky E: Activin-A attenuates several human natural killer cell functions. Blood 113, 3218-3225 (2009).
84. Hedger MP, Phillips DJ, De Kretser DM: Divergent cell-specific effects of activin-A on thymocyte proliferation stimulated by phytohemagglutinin, and interleukin 1β or interleukin 6 in vitro. Cytokine 595-602 (2000).
85. Brosh N, Sternberg D, Honigwachs-Sha'anani J et al.: The plasmocytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11. Identification as a stromal-derived activin A. J. Biol. Chem. 270, 29594-29600 (1995).